Benefits of Screening Mammography

Wendie A. Berg, MD, PhD


Breast cancer is a leading cause of premature death for women in their 40s, and mammographic screening significantly reduces the risk of death due to breast cancer. The latter was the conclusion of the US Preventive Services Task Force (USPSTF) meta-analysis of the randomized controlled trials (RCTs) of screening mammography. The USPSTF concluded, however, that the absolute benefit from routine mammographic screening of women in their 40s was too low to offset the harms. As a woman in her 40s, and a radiologist specializing in breast imaging, I find their conclusions puzzling.

Randomized controlled trials underestimate the true benefits of mammographic screening. They assess mortality reduction among women randomized to the group invited to be screened rather than those who actually participated in screening. In an RCT, an invited woman who never has a mammogram and dies of breast cancer is counted as having been screened, just as a woman in the control group who decides to have a mammogram outside the trial is counted as having not been screened. In several RCTs, mammographic quality was quite poor or only a single mammographic view was obtained, both of which reduce cancer detection.

Two observational studies among women who underwent screening mammography (with the current standard of 2 views of each breast), comprising millions of person-years of observation of both screened and unscreened populations, reported a 30% to 40% reduction in breast cancer mortality for women in their 40s. However, these observational data were not considered by the USPSTF, which limited its focus to RCTs. For women aged 40 to 49 years in a screening program, on average, about 1 in 460 will be diagnosed with breast cancer in any given year; during that decade of life, one in 69 women will be diagnosed with invasive breast cancer.

The incidence of breast cancer increases with age, particularly above age 40, with the rates at ages 45 to 49 years virtually identical to those at ages 50 to 54 years, and no abrupt change at age 50. At least a third of potential years of life lost to breast cancer occur among women who died of breast cancer after being diagnosed in their 40s. More than 40 000 women die from breast cancer each year, of whom 18% were diagnosed during their 40s (Carol DeSantis, Epidemiology and Surveillance Department, American Cancer Society, Atlanta, Georgia; unpublished analysis of Surveillance, Epidemiology, and End Results [SEER] Program, SEER 2000-2006 registries, Division of Cancer Control and Population Sciences, National Cancer Institute; December 10, 2009). Assuming a 30% reduction in breast cancer deaths due to screening, annual mammography prevents more than 2000 deaths per year among women diagnosed in their 40s in the United States.

Mammographic screening also increases the chance of detecting breast cancer small enough to be treated by lumpectomy instead of mastectomy and decreases the need for chemotherapy. Harms of treating more advanced disease and the increased risk of recurrence for women not screened by mammography were not considered by the USPSTF.
**Potential Harms of Mammographic Screening**

There are downsides associated with screening, but most women would not consider these harms. In a survey of 479 women, 63% felt that 500 or more false positives per life saved was a reasonable trade-off. According to estimates from the Breast Cancer Surveillance Consortium, for every 1000 women in their 40s screened once with mammography in the United States, 80 to 100 will be called back for additional evaluation, usually consisting of additional mammographic views and often ultrasound; 45 to 65 of those recalled have nothing of concern ("false positives"); 20 may be asked to return in 6 months, with the area followed having less than a 2% chance of malignancy; 15 will be recommended for biopsy, usually a needle biopsy; and 2 to 5 of women biopsied will be found to have breast cancer. There is a minimal theoretical concern that "0.05" women could develop cancer 10 to 30 years later from the small amount of radiation exposure from the mammogram; such "risk" is even lower for older women exposed to mammography.

A few indolent cancers that would not spread during the lifetime of the woman may be detected on the first mammogram and can result in potentially unnecessary treatment. Such overdiagnosis is likely uncommon (estimated at 4% of ductal carcinoma in situ) among new or enlarging findings on subsequent annual screens as the lesion has shown itself to be growing.

**Screening Only Women in Their 40s Who Are at Increased Risk**

Seventy-five percent of breast cancer is diagnosed in women with no obvious risk factors for breast cancer; therefore, the USPSTF recommendation against routine screening for women in their 40s in the absence of risk factors is problematic. Research is ongoing to develop and test other screening modalities for use in addition to mammography in women at increased risk. In women with dense breasts, in whom mammographic sensitivity is reduced, addition of screening ultrasound provides a 16% to 28% absolute increase in detection of node-negative breast cancer. In women at high risk, screening magnetic resonance imaging (MRI) improves detection of early breast cancer by 40% beyond mammography and ultrasound combined. Such increases in sensitivity come with significant increases in recall rates and needle biopsies. On average, 11% of needle biopsies prompted only by screening ultrasound and 40% of biopsies prompted only by screening MRI prove malignant.

**Clinical Breast Examination**

Clinical breast examination is much less effective than ultrasound or MRI, increasing early breast cancer detection by only 3% beyond mammography, with only 1% of suspicious findings proving malignant. Going forward, resources might be better spent on ultrasound in women with dense breasts than on clinical breast examination, although currently there is a shortage of trained personnel in breast ultrasound. The USPSTF recommended against teaching breast self-examination due to an increase in false-positive findings and lack of demonstrated benefit. However, women who notice changes in their breast(s) should bring that information to their clinician's attention.

**Annual or Biennial Screening**

Breast cancer in younger women tends to be more biologically aggressive. Estimates are that preclinical breast cancer has a 16% chance of spreading to lymph nodes
within 1 year in a woman in her 40s vs 7% for a woman in her 50s and 5% for a woman in her 60s. To achieve optimal benefit from mammography, a woman in her 40s would need to be screened every year.

**Continue Screening Mammography After Age 74 Years?**

As with women aged 40 to 74 years, screening mammography decreases the stage of disease at diagnosis and deaths due to breast cancer among women in their 70s and 80s. Average life expectancy of a US woman in her 80s is 8.6 years, so screening can be continued as long as a woman is in reasonably good health and would pursue treatment if cancer is identified.

In summary, screening mammography is the only test to date proven to reduce deaths due to breast cancer. Annual mammographic screening is appropriate starting at age 40 years, provided the woman is willing to accept the downsides of false positives, including being recalled for more imaging and the possibility of a needle biopsy for a finding that is not breast cancer. The overwhelming majority of women are willing to accept these downsides as part of the process of saving lives otherwise lost to breast cancer.

**AUTHOR INFORMATION**

**Corresponding Author:** Wendie A. Berg, MD, PhD, American Radiology Services, Johns Hopkins Green Spring, Lutherville, MD 21093 (wendieberg@gmail.com).

**Financial Disclosures:** Dr Berg reports being a consultant to Naviscan Inc and an uncompensated member of the medical advisory board of Medipattern Inc.

**Funding/Support:** Dr Berg is supported by grants from The Avon Foundation and National Cancer Institute (U01 CA079778 and U01 CA89008).

**Additional Contributions:** I thank Robert A. Smith, PhD, Cancer Control Sciences Department, American Cancer Society; R. Edward Hendrick, PhD, Department of Radiology, University of Colorado, Denver; and Daniel B. Kopans, MD, Department of Radiology, Massachusetts General Hospital, Harvard University School of Medicine, for helpful discussions. These individuals were not compensated for their contributions.

**Author Affiliation:** American Radiology Services, Johns Hopkins Green Spring, Lutherville, Maryland.

**REFERENCES**


